EP1555894A2 - Neue nutrazeutische und pharmazeutische zusammensetzungen und ihre verwendung - Google Patents

Neue nutrazeutische und pharmazeutische zusammensetzungen und ihre verwendung

Info

Publication number
EP1555894A2
EP1555894A2 EP03752849A EP03752849A EP1555894A2 EP 1555894 A2 EP1555894 A2 EP 1555894A2 EP 03752849 A EP03752849 A EP 03752849A EP 03752849 A EP03752849 A EP 03752849A EP 1555894 A2 EP1555894 A2 EP 1555894A2
Authority
EP
European Patent Office
Prior art keywords
oil
acid
pharmaceutical compositions
nutraceutical
compositions according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03752849A
Other languages
English (en)
French (fr)
Inventor
Ludovic Predal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synergia Holding
Original Assignee
Synergia Holding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergia Holding filed Critical Synergia Holding
Publication of EP1555894A2 publication Critical patent/EP1555894A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/003—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0053—Compositions other than spreads
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0056—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • the present invention relates to the field of organic chemistry and more particularly to the field of polyunsaturated fatty acids.
  • the present invention relates to pharmaceutical or nutraceutical compositions rich in unsaturated fatty acids intended for preventing or treating cardiovascular diseases in humans or animals.
  • neutraceutical or pharmaceutical compositions rich in unsaturated fatty acids characterized in that they contain ⁇ -linolenic acid in free or combined form, associated with fatty acids with five or six double bonds.
  • the invention effectively relates to a natural product rich in ⁇ -linolenic acid such as a vegetable oil, and more precisely kiwi seed oil, linseed oil, camelina oil ...
  • the ⁇ -linolenic acid can also be used in the form of a pure chemical or in the form of salts, in particular the sodium salt or the calcium salt or also in the form of an ester such as methyl ⁇ -linolenate, ethyl or glyceryl or in the form of an adsorbate in a cellulose derivative such as hydroxyethyl cellulose, hydroxypropyl methyl cellulose or even in cyclo dextrins.
  • the fatty acids with five double bonds are typically eicosapentaenoic acid which is found in abundance in fish oils such as halibut, cod liver oil, haddock, tuna, sardines or sharks. .
  • the six double bond acids are also derived from fish oils which are rich in docosahexaenoic acid in particular.
  • a well-known source of such a fatty acid is tuna oil or sardine oil ...
  • Polyunsaturated fatty acids can also exist in the form of concentrates, obtained in particular by molecular distillation of oils, thus making it possible to produce preparations containing up to 50% of a specific fatty acid.
  • Polyunsaturated fatty acids can also be obtained by supercritical fluid extraction of oils, using pressure variations. Polyunsaturated fatty acids can thus be obtained electively (see French patent 2,637,910, N. Hagsma et al. J. Am. Oil Chem Soc. 59 (1982) 147).
  • oils from Rib agencies and in particular oils from blackcurrant seeds or redcurrants in ⁇ -linolenic acid by formation of a solid complex with urea.
  • compositions according to the invention are characterized by a determined ratio between the different fatty acids in the mixture.
  • ⁇ -linolenic acid is mainly present at concentrations ranging from 70 to 90% of the total mass
  • eicosapentaenoic acid is present from 10 to 20% of the total mass
  • docosahexanenoic acid at 25 to 35% of the total mass of fatty acids.
  • a preparation according to the invention contains from 800 to 1000 mg of ⁇ -linolenic acid, from 80 to 120 mg of eicosapentaenoic acid and from 250 to 300 mg of docosaliexaenoic acid.
  • the content of ⁇ -linolenic acid may possibly be between 100 and 120 mg per preparation according to the invention.
  • associations have already been described containing different polyunsaturated fatty acids such as for example a granule containing from 2 to 7% of marine or vegetable oil containing ⁇ -linolenic acid, eicosapentaenoic acid and / or docosahexaenoic acid and other oils associated with a water-soluble vehicle. These granules are then used in the form of tablets, in pharmacies, as food supplements, as food products and as animal feed (see patent EP266,323).
  • fatty acids such as ⁇ -linolenic acid and / or its essential metabolites and in particular dihomo gammalinolenic acid and / or eicosapentaenoic acid, stearidonic acid, docosahexaenoic acid (DHA) or eicosapentaenoic acid (20 - 5 n-3) in which polyunsaturated fatty acids are used as such or in the form of a salt or other pharmacologically acceptable form, to prepare a medicament intended to treat or prevent an abnormal calcification of the soft tissues and vessels in humans and animals (see patent EP585 027A1).
  • the problem with such a composition according to the invention was to find a raw material containing large amounts of ⁇ -linolenic acid, preferably greater than 50% of the mass of oil.
  • Kiwi, flax or camelina seed oil is mainly such a source of ⁇ -linolenic acid.
  • Kiwi seed oil is an abundant raw material obtained from kiwi seeds either by specific extraction without solvent, or by solvent exhaustion.
  • the recommended daily intake of ⁇ -linolenic acid is approximately 2 g per day.
  • the total amount of kiwi seed oil to consume to reach this daily dose is 3 ml in total.
  • the compositions according to the invention find a valuable use in therapy and dietetics for the prevention and treatment of arteromatosis.
  • the interest in polyunsaturated fatty acids results from an epidemiological study carried out by Danish scientists on a sample of Eskimo population of Greenland whose rate of cardio-coronary diseases is particularly low. This effect could be attributed to polyunsaturated fatty acids (EPA and DHA in particular) of marine origin incorporated into their food.
  • compositions according to the invention are administered in the form of capsules containing up to 1,500 mg of oily compounds, given at a rate of 1 to 3 capsules per day.
  • compositions can also be in the form of granules, powders on a pulverulent support or in the form of drinkable emulsions.
  • the problem posed for the production of such compositions is to protect them from oxidation by atmospheric oxygen and from the effects of decomposition by light.
  • the use of tinted glasses, colored capsules reduces the effects.
  • a natural antioxidant such as tocopherols, or synthetic antioxidant such as BHA or TBA prevents oxidation or peroxidation phenomena.
  • a preferred composition according to the invention is that which contains, for a capsule of 1,500 mg, 900 mg of ⁇ -linolenic acid, 100 mg of EPA, 270 mg of DHA and optionally 115 mg of ⁇ -linolenic acid, the complement being formed from a neutral oil which does not become rancid.
  • Kiwi seed oil corresponding to 900 mg of ⁇ -linolenic acid
  • Sardine oil corresponding to 100 mg of eicosapentaenoic acid Tuna oil corresponding to 270 mg of docosahexaenoic acid
  • Borage oil corresponding to 115 mg of ⁇ -linolenic acid Almond oil qs for a capsule weighing 1,500 mg
  • Kiwi seed oil in an amount corresponding to 1,000 mg of ⁇ -linolenic acid. Concentrate of triglycerides of eicosapentaenoic acid and docosahexaenoic acid corresponding to 80 mg of eicosapentaenoic acid and 300 mg of docosaliexaenoic acid. Peanut oil in sufficient quantity for a soft capsule of 1,500 mg.
  • Kiwi seed oil corresponding to 800 mg of ⁇ -linolenic acid
  • Sardine oil corresponding to 100 mg of eicosapentaenoic acid
  • Shark oil corresponding to 200 mg of docosahexaenoic acid
  • Corn oil 10 ml Polysorbate 60 8 ml Glucose syrup 20 ml Water qs 100 ml Apricot flavor qs
  • Oral emulsion of ⁇ -linolenic acid Kiwi seed oil 25 g Sardine oil 12 g Tuna oil 20 g

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP03752849A 2002-05-22 2003-05-22 Neue nutrazeutische und pharmazeutische zusammensetzungen und ihre verwendung Withdrawn EP1555894A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0206205 2002-05-22
FR0206205A FR2839887A1 (fr) 2002-05-22 2002-05-22 Nouvelles compositions nutraceutiques et pharmaceutiques et leurs utilisations
PCT/FR2003/001544 WO2003097033A2 (fr) 2002-05-22 2003-05-22 Nouvelle compositions neutraceutiques et pharmaceutiques et leurs utilisations

Publications (1)

Publication Number Publication Date
EP1555894A2 true EP1555894A2 (de) 2005-07-27

Family

ID=29414968

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03752849A Withdrawn EP1555894A2 (de) 2002-05-22 2003-05-22 Neue nutrazeutische und pharmazeutische zusammensetzungen und ihre verwendung

Country Status (5)

Country Link
US (1) US7740885B2 (de)
EP (1) EP1555894A2 (de)
AU (1) AU2003258772A1 (de)
FR (1) FR2839887A1 (de)
WO (1) WO2003097033A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865353B1 (fr) * 2004-01-23 2009-01-09 Synergia Holding Nouveaux complements dietetiques ou alimentaires a base d'acide gras insature et leurs utilisation
NZ539698A (en) * 2005-04-29 2007-12-21 Vital Food Processors Ltd Kiwifruit seed oil extraction method and product
CA2567879C (en) * 2006-11-14 2013-03-26 Thomas Greither Nutritional food oil compositions and methods of making same
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8604117D0 (sv) * 1986-09-29 1986-09-29 Kabivitrum Ab Composition
FR2637910B1 (fr) 1988-10-18 1993-04-30 Azar Roger Nouveau procede d'obtention d'huile de pepins de cassis enrichie
JPH0748992B2 (ja) * 1990-04-16 1995-05-31 日本油脂株式会社 血栓防止用粉末組成物
US5223282A (en) * 1991-02-01 1993-06-29 Wm. Wrigley Jr. Company Methods of producing chewing gum using molten sorbitol and gum produced thereby
KR930006432B1 (ko) * 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
JPH06237734A (ja) 1991-11-06 1994-08-30 Sanwa Kagaku Kenkyusho Co Ltd 機能後退性疾患用食品組成物
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
GB9217781D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
JPH06169735A (ja) 1992-12-10 1994-06-21 Nippon Oil & Fats Co Ltd 栄養飲料組成物
JP3347381B2 (ja) * 1993-01-27 2002-11-20 協和醗酵工業株式会社 ペットフード
DE4304394A1 (en) * 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
FR2721517B1 (fr) * 1994-06-24 1996-08-30 Biovaleur Sa Composition pharmaceutique utilisée en tant que complément alimentaire.
FR2731015B1 (fr) 1995-02-24 1997-05-30 Sci Sartone Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus
US6630192B2 (en) * 1995-04-07 2003-10-07 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
US6596302B2 (en) * 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
DK1155620T3 (da) * 2000-05-18 2005-12-05 Mega Healthcare As Q Kosttilskudsmiddel med vitaminer, mineraler og flerumættede fedtsyrer
EP1181870A1 (de) * 2000-08-22 2002-02-27 Belovo Eggs & Egg Products Lipidemulsion als ausgewogene Nahrungsquelle für Vitamin F
EP1809727B1 (de) * 2004-11-04 2010-06-02 Monsanto Technology, LLC Verfahren zur herstellung von ölzusammensetzungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03097033A2 *

Also Published As

Publication number Publication date
US20070128292A1 (en) 2007-06-07
WO2003097033A2 (fr) 2003-11-27
WO2003097033A3 (fr) 2004-03-11
AU2003258772A1 (en) 2003-12-02
FR2839887A1 (fr) 2003-11-28
AU2003258772A8 (en) 2003-12-02
US7740885B2 (en) 2010-06-22

Similar Documents

Publication Publication Date Title
FR2553662A1 (fr) Composition d'acides gras combines, pour reduire les taux de triglycerides et de cholesterol du sang
JP2810916B2 (ja) 脂肪酸を含有する医薬用組成物
EP2124961B1 (de) Neuartige zusammensetzung auf der basis von cholest-4-in-3-on-oxim
FR2490631A1 (fr) Nouvelle composition lipidique utilisable en dietetique, reanimation et therapeutique
JP2009526033A (ja) オメガ３
JP2016504999A (ja) エイコサペンタエン酸（ｅｐａ）製剤
CN1714135A (zh) 含有高度不饱和脂肪酸、其盐或其酯的外用组合物
AU2003274548B2 (en) Conjugated linoleic acid compositions
CA1324527C (fr) Emulsion lipidique destinee a la nutrition parenterale ou enterale
LU87488A1 (fr) Compositions pharmaceutiques agissant en particulier sur le systeme cardiaque et cardiovasculaire et procede pour les preparer
JP2022511537A (ja) 超長鎖脂肪酸組成物
EP0796238B1 (de) Verfahren zur stabilisation der polyungesättigten fettsäuren und verwendung dieser stabilisierten produkten in therapie und in kosmetologie
WO1996002488A9 (fr) Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises en therapeutique et en cosmetologie
CN1796388B (zh) 芝麻素/异芝麻素组合物
EP2003990A2 (de) Kombination einer öligen substanz mit einer mischung von mindestens zwei cyclodextrinen
EP1147167A1 (de) Verfahren zur gewinnung von einem mit hydroxyoctadecadiensäuren (hode) oder ihren estern angereicherten öl aus einem linolsäure oder ihre ester enthaltenden ölartigen gemisch
JPS63104917A (ja) コレステロール低下または上昇抑制剤
EP1555894A2 (de) Neue nutrazeutische und pharmazeutische zusammensetzungen und ihre verwendung
LU87170A1 (fr) Compositions dietitiques et procede pour leur preparation
FR2612399A1 (fr) Compositions pharmaceutiques agissant sur le coeur et le systeme cardiovasculaire et procede pour leur preparation
EP0055172B1 (de) Arzneimittel enthaltend Proteinhydrolysate und an polyungesättigten Fettsäuren reiche Lipide
JPH0759540A (ja) アラキドン酸含有健康食品
EP4475829A1 (de) Zusammensetzung mit einer mischung aus dha und/oder epa und einem pflanzlichen phospholipid
JP4904751B2 (ja) 生体内ｄｈａ合成促進剤
CA2842870C (fr) Extraction liquide/liquide avec un solvant comprenant au moins 5 atomes de carbone et 1 ou 2 atomes d'oxygene

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050524

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140527